文献速递重症综合管理与镇静镇痛消化、代谢与肾脏急症

肝素结合蛋白(HBP):脓毒症诱导急性肾损伤的致病标志物及肝素治疗潜在靶点

Heparin-Binding Protein (HBP): A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury.
PubMed 文献 · Shock · 2017-01-01
一句话结论在脓毒症休克患者中,血浆HBP水平升高与脓毒症诱导急性肾损伤(AKI)的发生相关,HBP参与其病理生理过程,肝素衍生物可体外和体内阻断HBP的促炎效应,作者建议可测试肝素预防脓毒症诱导AKI的疗效与安全性。

该研究基于多中心随机对照试验VASST中296例脓毒症休克患者,发现血浆HBP水平在发生AKI及需要肾脏替代治疗(RRT)的患者中显著更高,HBP识别中度AKI的曲线下面积(AUC)为0.85。体外实验中,重组HBP可增加肾小管上皮细胞IL-6产生,不同肝素衍生物可阻断HBP诱导的炎症反应。小鼠体内实验显示,肝素衍生物同样可阻断HBP引起的肾脏炎症征象。作者结论认为,血浆HBP升高与脓毒症诱导AKI的发生相关且参与其病理生理,肝素或可被测试用于预防脓毒症诱导AKI的疗效与安全性。

要点

  • 在296例脓毒症休克患者中,血浆HBP水平在发生AKI的患者中显著更高。
  • 血浆HBP水平在需要肾脏替代治疗(RRT)的脓毒症休克患者中显著更高。
  • HBP识别中度AKI的曲线下面积(AUC)为0.85。
  • 重组HBP可增加肾小管上皮细胞IL-6产生,不同肝素衍生物在体外和体内均可阻断HBP诱导的炎症反应。
  • 作者认为,肝素或可被测试用于预防脓毒症诱导AKI的疗效与安全性。

适用人群与场景

  • 来自随机多中心VASST试验的296例脓毒症休克患者。

诊断标准与关键阈值

  • 血浆HBP水平识别中度AKI的曲线下面积(AUC)为0.85。

研究设计与关键结果

  • 研究类型为基于随机多中心VASST试验的分析,纳入296例脓毒症休克患者,血浆HBP水平与AKI发生及需要肾脏替代治疗(RRT)相关。
  • 血浆HBP水平在发生AKI的患者中显著更高,在需要RRT的患者中也显著更高。
  • HBP识别中度AKI的AUC为0.85。
  • 体外实验中,重组HBP可增加肾小管上皮细胞IL-6产生;不同肝素衍生物在体外可阻断HBP诱导的炎症反应增强。
  • 小鼠体内实验中,肝素衍生物可阻断HBP引起的肾脏炎症征象。

证据类型、等级与局限

  • 证据类型为基于随机多中心VASST试验的分析、体外细胞实验及小鼠体内实验。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,肝素或可被测试用于预防脓毒症诱导AKI的疗效与安全性。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

RATIONALE: Sepsis-induced acute kidney injury (AKI) is a common condition with high morbidity and mortality. Neutrophil-derived heparin-binding protein (HBP) induces vascular leakage and is a promising biomarker of sepsis-induced organ dysfunction. It remains unknown if HBP is prognostic of AKI in septic shock and if HBP could play a role in the pathophysiology of sepsis-induced AKI.

OBJECTIVES: To determine the association of plasma HBP levels with development of AKI, investigate the role of HBP in the pathophysiology of sepsis-induced AKI, and test the effect of blocking HBP using heparin derivatives.

METHODS: In 296 septic shock patients from the randomized multicenter Vasopressin and Septic Shock Trial (VASST) plasma HBP levels were associated with development of AKI and need for renal replacement therapy (RRT). Human renal tubular cells were exposed to recombinant HBP to evaluate inflammation and heparin derivatives were used to abrogate these effects. Finally, mice were exposed to HBP with and without heparin derivatives and the kidneys examined for signs of inflammation.

FINDINGS: Plasma HBP levels were significantly higher in patients with AKI and those requiring RRT. HBP levels identified patients with moderate AKI with an area under curve (AUC) of 0.85. HBP increased IL-6 production in renal tubular epithelial cells. Different heparin derivatives abrogated the HBP-induced increased inflammatory response in vitro and in vivo.

CONCLUSION: Elevated plasma HBP is associated with development of sepsis-induced AKI and HBP is involved in its pathophysiology. Our studies suggest that heparin(s) could be tested for efficacy and safety of prevention of sepsis-induced AKI.

来源:Shock,查看原文。版权归原作者所有。

参考来源

  1. Fisher J, Russell JA, Bentzer P, et al. Heparin-Binding Protein (HBP): A Causative Marker and Potential Target for Heparin Treatment of Human Sepsis-Induced Acute Kidney Injury. Shock. 2017. PMID: 28319494. doi:10.1097/SHK.0000000000000862

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。